AstraZeneca Annual Report and Form 20-F Information 2008

Notes to the Financial Statements (Group)

• 1 Operating profit
• 2 Finance income and expense
• 3 Taxation
• 4 Earnings per $0.25 Ordinary Share
• 5 Segment information

2 Finance income and expense

	2008  $m	2007  $m	2006  $m
Finance income Returns on fixed deposits and equity securities	15	52	29
Returns on short-term deposits	127	298	330
Expected return on post-employment defined benefit plan assets	584	573	518
Fair value gains on debt, interest rate swaps and investments	128	36	11
Total finance income	854	959	888
Finance expense Interest on debt and commercial paper	(664)	(513)	(59)
Interest on overdrafts and other financing costs	(50)	(9)	(13)
Interest on post-employment defined benefit plan liabilities	(589)	(539)	(475)
Fair value charges on debt, interest rate swaps and investments	(2)	(6)	–
Net exchange losses	(12)	(3)	(14)
Total finance expense	(1,317)	(1,070)	(561)
Net finance (expense)/income	(463)	(111)	327

The amount of exchange gains and losses recognised in income, other than those arising on financial instruments measured at fair value through profit or loss in accordance with IAS 39 (see Note 16), is a loss of $12m (2007: $3m; 2006: $14m).

Back to the top